NBI-98854: Preliminary Phase IIa data

Preliminary data from an open-label, dose-escalation, Canadian Phase IIa trial in 6 evaluable schizophrenic patients with moderate to severe tardive dyskinesia showed that once-daily NBI-98854 reduced...